



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

October 25, 2019

Michael Favish  
Chief Executive Officer  
Guardion Health Sciences, Inc.  
15150 Avenue of Science, Suite 200  
San Diego, CA 92128

**Re: Guardion Health Sciences, Inc.**  
**Preliminary Proxy Statement on Schedule 14A**  
**Filed October 18, 2019**  
**File No. 001-38861**

Dear Mr. Favish:

We have reviewed your filing and have the following comment.

Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to the comment, we may have additional comments.

Preliminary Proxy Statement on Schedule 14A

Proposal 3: Amendment of Certificate of Incorporation to increase Number of Authorized Common Stock, page 18

1. Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the charter amendment.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Michael Favish  
Guardion Health Sciences, Inc.  
October 25, 2019  
Page 2

You may contact Joseph McCann at (202) 551-6262 or Mary Beth Breslin, Legal Branch Chief, at (202) 551-3625 if you have questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: David Sunkin